Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
M D'Huyvetter, J De Vos, V Caveliers… - Journal of Nuclear …, 2021 - Soc Nuclear Med
131I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a targeted
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single …
radionuclide theranostic agent directed at HER2-expressing cancers. VHH1 is a single …
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
R Laforest, SE Lapi, R Oyama, R Bose… - Molecular imaging and …, 2016 - Springer
Purpose The purpose of the present study is to evaluate safety, human radiation dosimetry,
and optimal imaging time of [89 Zr] trastuzumab in patients with HER2-positive breast …
and optimal imaging time of [89 Zr] trastuzumab in patients with HER2-positive breast …
SPECT/CT imaging of the novel HER2-targeted peptide probe 99mTc-HYNIC-H6F in breast cancer mouse models
L Li, Y Wu, Z Wang, B Jia, Z Hu, C Dong… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Overexpression of human epidermal growth factor receptor 2 (HER2) plays important roles
in tumorigenesis and tumor progression in breast cancer. Nuclear imaging of HER2 …
in tumorigenesis and tumor progression in breast cancer. Nuclear imaging of HER2 …
[HTML][HTML] Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers
Y Feng, R Meshaw, D McDougald, Z Zhou, XG Zhao… - Scientific Reports, 2022 - nature.com
Radiopharmaceutical therapy (RPT) is an attractive strategy for treatment of disseminated
cancers including those overexpressing the HER2 receptor including breast, ovarian and …
cancers including those overexpressing the HER2 receptor including breast, ovarian and …
111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified …
DL Costantini, C Chan, Z Cai, KA Vallis… - Journal of Nuclear …, 2007 - Soc Nuclear Med
The cytotoxicity and tumor-targeting properties of the anti-HER2/neu monoclonal antibody
trastuzumab modified with peptides (CGYG PKKKRKV GG) harboring the nuclear …
trastuzumab modified with peptides (CGYG PKKKRKV GG) harboring the nuclear …
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Purpose: Camelid single-domain antibody-fragments (sdAb) have beneficial
pharmacokinetic properties, and those targeted to HER2 can be used for imaging of HER2 …
pharmacokinetic properties, and those targeted to HER2 can be used for imaging of HER2 …
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction
INTRODUCTION: Radioimmunotherapy with anti-HER2 monoclonal antibodies (mAbs) such
as trastuzumab is a promising strategy for treating HER2-positive breast and ovarian …
as trastuzumab is a promising strategy for treating HER2-positive breast and ovarian …
111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
SBM Gaykema, JR de Jong, PJ Perik… - Molecular …, 2014 - journals.sagepub.com
Human epidermal growth factor receptor (HER) 2 imaging with radiolabeled trastuzumab
might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 …
might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 …
Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron–emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by …
DL Costantini, K Bateman, K McLarty… - Journal of Nuclear …, 2008 - Soc Nuclear Med
Our goals in this study were to determine whether 111In-trastuzumab coupled to peptides
harboring nuclear localizing sequences (NLSs) could kill trastuzumab-resistant breast …
harboring nuclear localizing sequences (NLSs) could kill trastuzumab-resistant breast …
Phase I trial of 99mTc-(HE) 3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer
O Bragina, V Chernov, A Schulga… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2)
expression may enable a noninvasive discrimination between HER2-positive and HER2 …
expression may enable a noninvasive discrimination between HER2-positive and HER2 …